Form 4: ORIC CFO Sells Shares After Option Exercise

Oric Pharmaceuticals' CFO, Dominic Piscitelli, executed a pre-arranged sale of 11,000 common shares following the exercise of stock options.

Summary

• Dominic Piscitelli, Chief Financial Officer of Oric Pharmaceuticals, Inc. (ORIC), reported a transaction involving the exercise of stock options and subsequent sale of common stock.
• On October 6, 2025, Mr. Piscitelli exercised options to acquire 11,000 shares of common stock at an exercise price of $4.36 per share.
• Immediately following the exercise, he sold 11,000 shares of common stock at a weighted average price of $14.5199 per share, with individual sales ranging from $14.50 to $14.53.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 24, 2025.
• After these transactions, Mr. Piscitelli beneficially owns 48,317 shares of common stock directly.
• He also holds 196,500 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the officer realized a profit (positive for the individual), the sale of shares, even under a 10b5-1 plan, is a routine event for the company and does not inherently signal a positive or negative outlook for the business itself.

Positives

• The Chief Financial Officer realized a significant gain from the exercise of stock options and subsequent sale of shares, indicating personal financial benefit.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which suggests a planned and systematic approach to managing equity holdings rather than a reaction to new, undisclosed information.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived by some investors as a lack of confidence, although this is often a routine liquidity event.

Risks

• No new specific risks are introduced by this routine insider transaction report.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan, which typically has minimal direct impact on other shareholders. It provides transparency regarding executive equity holdings.
• Reporting Person (Dominic Piscitelli): The transaction resulted in a significant personal financial gain from monetizing stock options.

Key Dates

Keywords

Oric Pharmaceuticals, ORIC, Dominic Piscitelli, CFO, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Equity Compensation